Want to see HK:1672 full AI Analyst Report?
Ascletis Pharma, Inc. (1672) AI Stock Analysis
Top Page
Ascletis Pharma, Inc.
(HKEX:1672)
The score is primarily held down by weak financial performance—revenue collapse, deeply negative margins, and sustained negative free cash flow with elevated burn—despite low leverage on the balance sheet. Technicals reinforce the risk with a sustained downtrend (price below major moving averages and negative MACD). Valuation provides limited support because the company is loss-making (negative P/E) and no dividend yield is available.
Ascletis Pharma, Inc. (1672) vs. iShares MSCI Hong Kong ETF (EWH)
- Market Cap
- HKD 5.15B
- Dividend Yield
- ―
- Average Volume (3M)
- 2.25M
- Price to Earnings (P/E)
- -7.0
- Beta (1Y)
- 1.06
- Revenue Growth
- -59.39%
- EPS Growth
- -130.04%
- Country
- Hong Kong
- Employees
- 217
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Ascletis Pharma, Inc. Business Overview & Revenue Model
Company Description
Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China. The company’s commercial products include Ritonavir tablet; and ASCLEVIR and GANOVO...
How the Company Makes Money
Ascletis primarily makes money through (1) product sales of its commercialized prescription drugs in its served markets, where revenue is recognized from selling finished pharmaceutical products through distribution channels to hospitals, pharmacies,...
Ascletis Pharma, Inc. Financial Statement Overview
Summary
Overall financial profile is weak due to collapsing revenue, very negative profitability, and sustained negative operating/free cash flow with sharply higher burn in 2024–2025. The main offset is a relatively strong balance sheet from a leverage standpoint (very low debt-to-equity), which reduces near-term solvency risk but does not resolve the ongoing loss and cash-burn trajectory.
Income Statement
18Very NegativeBalance Sheet
74PositiveCash Flow
24Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 947.00K | 2.03M | 1.28M | 56.60M | 54.09M | 76.88M |
| Gross Profit | -8.18M | 527.00K | 735.00K | 25.99M | -24.69M | 39.17M |
| EBITDA | -364.30M | -466.92M | -384.18M | -126.09M | -284.50M | -169.35M |
| Net Income | -591.95M | -359.88M | -300.94M | -144.72M | -314.84M | -199.02M |
Balance Sheet | ||||||
| Total Assets | 2.45B | 2.07B | 2.12B | 2.49B | 2.66B | 2.83B |
| Cash, Cash Equivalents and Short-Term Investments | 2.27B | 1.90B | 1.95B | 2.30B | 2.48B | 2.50B |
| Total Debt | 3.74M | 5.16M | 7.63M | 8.42M | 4.24M | 2.75M |
| Total Liabilities | 179.10M | 129.93M | 158.41M | 148.94M | 117.16M | 100.89M |
| Stockholders Equity | 2.27B | 1.94B | 1.97B | 2.34B | 2.54B | 2.73B |
Cash Flow | ||||||
| Free Cash Flow | -502.02M | -330.83M | -343.73M | -163.32M | -156.85M | -154.13M |
| Operating Cash Flow | -500.13M | -329.23M | -341.58M | -144.16M | -142.45M | -146.93M |
| Investing Cash Flow | -1.49B | 565.97M | 978.91M | 149.84M | -1.30B | -274.49M |
| Financing Cash Flow | 1.06B | 336.29M | -103.51M | -81.50M | -1.42M | -31.10M |
Ascletis Pharma, Inc. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1672, the sentiment is Negative. The current price of 4.90 is below the 20-day moving average (MA) of 6.44, below the 50-day MA of 8.25, and below the 200-day MA of 12.20, indicating a bearish trend. The MACD of -0.93 indicates Positive momentum. The RSI at 24.20 is Positive, neither overbought nor oversold. The STOCH value of 6.88 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:1672.
Ascletis Pharma, Inc. Peers Comparison
Overall Rating
HK:996965Neutral
HK:685550.1Neutral
HK:261646.6Neutral
HK:968846Neutral- HK:167244Neutral
HK:187741.25Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| HK:9969 | 65Neutral | HKD 16.81B | 12.42 | 17.47% | ― | 146.27% | ― |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| HK:6855 | 50Neutral | HKD 10.12B | -5.93 | -153.78% | ― | 70.26% | -12.79% |
| HK:2616 | 47Neutral | HKD 7.77B | -15.53 | -43.54% | ― | 116.67% | -0.42% |
| HK:9688 | 46Neutral | HKD 21.69B | -12.70 | -27.40% | ― | 5.38% | 16.86% |
| HK:1672 | 44Neutral | HKD 5.15B | -7.05 | -28.15% | ― | -59.39% | -130.04% |
| HK:1877 | 41Neutral | HKD 30.07B | -69.15 | -7.23% | ― | 35.82% | 54.40% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| HK:1672 | Ascletis Pharma, Inc. | 4.90 | -4.91 | -50.05% | |
| HK:9688 | Zai Lab Ltd | 17.37 | -3.65 | -17.36% | |
| HK:9969 | InnoCare Pharma Ltd. | 11.25 | -3.37 | -23.05% | |
| HK:1877 | Shanghai Junshi Biosciences Co., Ltd. Class H | 15.26 | -11.44 | -42.85% | |
| HK:2616 | CStone Pharmaceuticals | 4.94 | -1.28 | -20.58% | |
| HK:6855 | Ascentage Pharma Group International | 27.20 | -40.70 | -59.94% |
Ascletis Pharma, Inc. Corporate Events
Ascletis’ Oral GLP-1 Drug Shows Strong Phase II Diabetes Data With Solid Safety Profile
Ascletis reported positive topline data from a 13-week U.S. Phase II trial of its oral GLP-1 receptor agonist ASC30 in 100 participants with type 2 diabetes, with all tested doses meeting primary and secondary endpoints. The once-daily tablet achieve...
Ascletis Submits FDA IND for New Oral Amylin Agonist to Treat Obesity
Ascletis Pharma Inc., a Hong Kong-listed biopharmaceutical company, develops oral small-molecule and peptide drugs for metabolic diseases, including obesity, supported by its AI-assisted discovery platform. Its pipeline features the Phase III oral in...
Ascletis Partner Sagimet Starts Pivotal U.S. Phase III Trial of Acne Drug Denifanstat
Ascletis’ strategic partner Sagimet Biosciences has dosed the first patient in AURORA, a pivotal U.S. Phase III clinical trial of denifanstat (ASC40) in adults and adolescents aged 12 and older with moderate to severe acne. The study, designed...
Ascletis touts positive preclinical data for once-weekly oral obesity peptide pipeline
Ascletis Pharma has unveiled positive preclinical data for what it calls the industry’s most comprehensive once-weekly oral peptide pipeline for obesity and metabolic disorders. The lead candidate, ASC36o, a once-weekly oral amylin receptor ago...
Ascletis touts ultra-long-acting obesity candidate with strong preclinical weight-loss data
Ascletis Pharma Inc. has presented key preclinical data at the EASD 2026 meeting in Milan for ASC36_35FDC, a fixed-dose combination of an amylin receptor agonist and a GLP-1R/GIPR dual agonist designed as a once-monthly to once-quarterly injection. I...
Ascletis reports strong early U.S. trial data for oral psoriasis drug ASC50
Ascletis Pharma has reported positive Phase I proof-of-concept data from a randomized, double-blind, placebo-controlled 28-day clinical trial in the U.S. for ASC50, its in-house discovered oral small-molecule IL-17A inhibitor for mild-to-moderate pla...
Ascletis Starts U.S. Phase I Trial of Oral Obesity Drug ASC36
Ascletis Pharma Inc. has initiated a Phase I clinical trial in the U.S. for ASC36 oral tablets, an in-house discovered amylin receptor peptide agonist designed to treat obesity and overweight patients. The study, cleared under an FDA IND, will assess...
Ascletis Pharma Shares Added to Shanghai and Shenzhen-Hong Kong Stock Connect
Ascletis Pharma Inc. announced that its ordinary shares have been included as eligible securities under the Shanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock Connect programs, effective September 7, 2026. This inclusion allows eligible in...
Ascletis Deepens R&D Push as Loss Widens on Obesity Drug Pipeline
Ascletis Pharma reported interim unaudited results for the first half of 2026 showing total income of RMB 52.98 million, down nearly 49% year on year, while research and development spending more than doubled to RMB 341.66 million, driving its net lo...
Ascletis Starts Global Phase III Trials of Oral GLP‑1 Drug ASC30 for Obesity
Ascletis Pharma has begun dosing the first participant in its global Phase III AURORA program for ASC30, an investigational once‑daily oral GLP‑1 receptor agonist for chronic weight management and diabetes. The two pivotal, randomized, pl...
Ascletis Widens Loss on R&D Surge as Obesity Drug Pipeline Advances
Ascletis Pharma has warned investors that it expects to post a loss attributable to shareholders of about RMB319.7 million for the six months ended June 30, 2026, a more than threefold increase from the RMB88.0 million loss a year earlier. Despite th...
Ascletis Starts U.S. Phase I Trials for Ultra-Long-Acting Obesity Injections
Ascletis Pharma has initiated two Phase I obesity trials in the U.S. for ASC36, a once-monthly to once-quarterly amylin receptor peptide agonist, and ASC36_35FDC, a once-monthly fixed-dose combination of ASC36 with GLP-1R/GIPR dual agonist ASC35. The...
Ascletis launches global Phase III obesity trial and advances oral triple agonist portfolio
Ascletis Pharma has launched a global Phase III program for its once-daily oral GLP-1 small molecule candidate ASC30, targeting chronic weight management in about 4,600 obese or overweight patients across the U.S., Europe, and Canada. The trials will...
Ascletis Pharma Schedules Board Meeting to Review 2026 Interim Results and Dividend
Ascletis Pharma Inc. has announced that its board of directors will convene on August 31, 2026, to review and approve the interim financial results for the six months ended June 30, 2026. The board will also consider the potential declaration and pay...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 09, 2026